Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (2025)
49 slides from Cyclopharm's shareholder meeting presentation, 2025
Slide 1: 2025 Annual General Meeting
2025 Annual General Meeting
Slide 2: Safe Harbour Statement
Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the
Slide 3: Welcome
S cyclopharm WELCOME Mr David Heaney —
Slide 4: Chairman's Address
CHAIRMAN’S ADDRESS Mr David Heaney 4
Slide 5: Australian innovation entering a new era of Nuclear Pulmonology driven by AI
Australian innovation entering a new era of Nuclear Pulmonolgy driven by AI Technegas is now available in 66 countries. Direct distribution in 17 countries. Over 5.0 million patient procedures to date Recently approved in the US Leveraging global infrastructure with Business Partner Product distribu
Slide 6: Technegas in 66 countries with a strong second half of 2024
1 TechnegasTM in 66 countries with a strong second half of 2024 supporting record global sales up 5% on the prior corresponding period (pcp) 2 TechnegasTM installed at 33 US sites at 30 May 2025 with conservative growth estimates of 250 – 300 total installations by second half 2026. 3 US contracts c
Slide 7: Managing Director's Address
MANAGING DIRECTOR’S ADDRESS Mr James McBrayer 7
Slide 8: 2024 Full Year Financial Results
2024 Full Year Financial Results
Slide 9: Record Sales Revenue $27.6m
Record Sales Revenue • $27.6m up 5% from $26.3m in the pcp • Global sales revenue up 5% from the pcp to $15.2 million, with a Technegas strong second half up 14%, driven by initial US sales. 3rd Party Distribution • Global revenue up 4% from the pcp to $12.4 million • Initial US Technegas sales driv
Slide 10: 2024 Trading Highlights
2024 Trading Highlights Group Revenue Trend by Category (last 3 years) • Underpinned by PAS1 sales delivering 72.6% of revenue compared to 70.7% in $30m Technegas the pcp • 55 system sales compared to 58 in the $25m pcp (excluding USA) • Capital projects revenue up 83% in the $20m 2nd half but overa
Slide 11: Understanding Technegas
Understanding Technegas
Slide 12: Unique Drug + Device + Service combination = regulatory barrier to entry
Unique Drug + Device + Service combination = regulatory barrier to entry Technegas comprises the following components SYSTEM PER PATIENT CONSUMABLES SUPPORT USFDA Drug-Device TECHNEGAS PLUS SYSTEM TECHNEGAS ® SYSTEM PACK Combination product Technegas (Crucible) Technegas® Training Contacts Razor - R
Slide 13: Understanding Third Party Products
Understanding Third Party Products
Slide 14: Leveraging our Sales, Service & Regulatory Footprint in our Direct Markets
Leveraging our Sales, Service & Regulatory Footprint in our Direct Markets Third-Party Products comprise the following components Direct sales and Service in 17 Consumables and Equipment Sales SUPPORT out of 66 approved markets Radiopharmaceuticals Hotcells for Radiopharmaceutical Patient Injectors
Slide 15: Technegas USA Expansion
Technegas USA Expansion
Slide 16: Establishing a Network of Key Opinion Leader Locations
Establishing a Network of Key Opinion Leader Locations Rollout Update as of 30 May 2025: 33 US installations to date Sales Generated since approval: $US1million (A$1.6million) @ 31 March 2025 $US1.35 million (A$2.16 million) @ 30 May 2025 CMS Pass Through reimbursement granted Contracts secured in J
Slide 17: Potential applications across the entire field of respiratory medicine
Potential applications across the entire field of respiratory medicine Technegas (kit for the preparation of technetium Tc99m labeled carbon inhalation aerosol) for oral inhalation use – NDA 022335 ------------------USFDA APPROVED INDICATIONS AND USAGE------------------- TECHNEGAS, when used with so
Slide 18: Technegas - the ventilation imaging agent of choice in established markets
Technegas - the ventilation imaging agent of choice in established markets Survey conducted before Technegas USA launch highlights that: 85% of nuclear medicine ventilation studies ex-USA are performed using Technegas Xenon-133 has been displaced in all markets where Technegas is available SPECT ima
Slide 19: Placement Model to Expedite Consumable Demand
Placement Model to Expedite Consumable Demand US$7k one-off installation and Targeting 2,000 of the 8,000 US nuclear medicine departments. 250-300 total installations achieved training fee during the second half 2026. System Placement model supports rapid uptake US$7k p.a. technology fee, includes b
Slide 20: Best-in-Class Global Technology
Best-in-Class Global Technology - Technegas® is widely regarded as the world’s leading nuclear medicine functional 1 ventilation imaging agent, with more than 5 million patient procedures performed globally. Broad FDA Indication - US FDA approval includes a wide-ranging indication for use in lung im
Slide 21: Beyond PE: Blue Sky
Beyond PE: Blue Sky
Slide 22: Evolution of Ventilation Imaging
Evolution of Ventilation Imaging PLANAR SPECT SPECT/CT SPECT/CT Future Quantification A.I.2023 Applications 1986 22 Lobar distribution of ventilation AI reaching to segmental and subsegmental level analysis leading to chronic condition management and Treatable Trait identification Function + Anatomy
Slide 23: Clinical trials already underway
Clinical trials already underway *Including PE applications. On a long-term basis. 1. Roach PJ, et al. J Nucl Med 2013; 54: 1588-1596 10. Bajc M, et al.. Int J Chron Obstruct Pulm Dis 2017; 12: 1579- 17. Tee, et al; Intrevent Pulmonology; 2021, DOI 2. Ohira H, et al. J Nucl Cardiol 2015;22(1): 141-1
Slide 24: Beyond Pulmonary Embolism Initiatives Underway
Beyond Pulmonary Embolism Initiatives Underway 7 Cyclopharm sponsored Beyond PE clinical trials Hunter Medical Research Institute (Newcastle, AU): Diagnosis and response to therapy in severe asthma and COPD1 1 100 Patient Study * 100% Recruited * Study Published6, Woolcock Institute (Sydney, AU): Di
Slide 25: Cyclopharm Outlook
Ss cyclopharm Cydop narm Outlook ——
Slide 26: Upcoming Milestones and Growth Catalysts
250–300 US installations during the second half of 2026. Sales Force expansion to meet Upcoming demand. Milestones and Targeting clinical initiatives to expand the use of Technegas Growth Catalysts Beyond PE New third-party opportunities to further broaden our reach Leveraging an established
Slide 27: Outlook: 250-300 Technegas USA Total Installations by Second Half 2026
Outlook: 250 - 300 Technegas USA Total Installations achieved during Second Half 2026 Profitable and First in Class USFDA Approval Granted Recurring Revenue Technegas Product Growing MedTech Established Gold Standard Set to quadruple the size From single patient expansion Underlying business (ex- Pr
Slide 28: Formal Business
FORMAL BUSINESS Mr David Heaney 28
Slide 29: 2025 AGM - Formal Business
2025 AGM – Formal Business Resolutions 1 Financial Statements and Reports – (b) Remuneration Report 2 Re-election of Ms Dianne Angus as Director 3 Approval of grant of performance rights 4 Approval of grant of performance rights to the Managing Director for FY25 STI 5 Approval of grant of performanc
Slide 30: CYC AGM 2025 Resolutions: Remuneration Report
CYC AGM 2025 Resolutions 1b “That the Remuneration Report as set out in the Annual Report of the Company for the financial year ended 31 December 2024 be adopted.” Resolution For Against Discretionary Exclusions Abstain Remuneration Report 59,178,529 283,084 54,267 3,051,770 4,182 Questions? 30
Slide 31: CYC AGM 2025 Resolutions: Re-election of Director
CYC AGM 2025 Resolutions 2 “That, for the purposes of ASX Listing Rule 14.4 and for all other purposes, Ms Dianne Angus, who retires at the close of this Annual General Meeting and, being eligible, and having consented to act, be re-elected as a Director of the Company.” Resolution For Against Discr
Slide 32: CYC AGM 2025 Resolutions: Performance Rights
CYC AGM 2025 Resolutions 3 “That, for the purposes of ASX Listing Rule 7.2 (exception 13(b)) and for all other purposes, approval is given for the grant of up to 4 million performance rights in the Company under the Plan within 3 years from the date of this resolution, on the terms and conditions se
Slide 33: CYC AGM 2025 Resolutions: MD FY25 STI
CYC AGM 2025 Resolutions 4 “That, for the purposes of ASX Listing Rule 10.14, section 200E of the Corporation Act 2001 (Cth) and for all other purposes, approval be and is hereby given to the grant to the Managing Director (or his nominee) of performance rights over Shares having a value of up to $2
Slide 34: CYC AGM 2025 Resolutions: MD FY25 LTI
CYC AGM 2025 Resolutions 5 “That, for the purposes of ASX Listing Rule 10.14, section 200E of the Corporation Act 2001 (Cth) and for all other purposes, approval be and is hereby given to the grant to the Managing Director (or his nominee) of performance rights over Shares having a value of up to $2
Slide 35: CYC AGM 2025 Resolutions: Non-executive Director Remuneration
CYC AGM 2025 Resolutions 6 “That for the purposes of Listing Rule 10.17 and for all other purposes, the shareholders of the Company approve the increase of the maximum aggregate amount payable to non- executive directors by way of directors' fees from $450,000 to $600,000.” Resolution For Against Di
Slide 36: CYC AGM 2025 Resolutions: Placement Shares
CYC AGM 2025 Resolutions 7 “That for the purposes of Listing Rule 7.4 and for all other purposes, shareholders ratify the issue of 14,084,508 fully paid ordinary shares at an issue price of A$1.42 (Placement Shares) issued by a way of a placement to sophisticated and professional investors and other
Slide 37: 2025 AGM - Proxy Summary
2025 AGM – Proxy Summary Resolution For Against Discretionary Exclusions Abstain 1(b). Remuneration Report 59,178,529 283,084 54,267 3,051,770 4,182 2. Re-election of Director 62,476,956 27,700 55,143 - 12,500 3. Approval of grant of performance rights 59,314,524 460,862 50,143 - 2,746,770 4. Approv
Slide 38: Thank You
S cyclopharm : THANK YOU =
Slide 39: Questions
Questions
Slide 40: Attachment Section
Attachment Section
Slide 41: Technegas Supplemental Information
Technegas Supplemental Information
Slide 42: Functional Imaging showing where Oxygen is distributed within the lung
Functional Imaging showing where Oxygen is distributed within the lung Technegas is composed of 99mTc cores encapsulated within layers of graphite to form individual hexagonal plate-like particles.1-2 Technegas is manufactured by heating Technetium-99m in a carbon crucible within an argon environmen
Slide 43: Technegas is the nuclear medicine agent of choice in established markets
Technegas is the nuclear medicine agent of choice in established markets Endorsed by the guidelines from the European1-2 and the Canadian3 Associations of Nuclear Medicine (EANM & CANM) “ Using 99m-Tc-Technegas® is according to clinical experience better than the best aerosols ” “ Technegas® facilit
Slide 44: Recent Research and Articles Driven by Clinicians and End Users
Recent Research and Articles Driven by Clinicians and End Users: Technegas -Technegas at Last! Implementing Technegas into Clinical Practice in the United States: Considerations, Challenges, and Recommendations Delynn Silvestros and Tina M. Buehner; Journal of Nuclear Medicine Technology March 2025,
Slide 45: V/Q SPECT/CT is superior compared to CTPA
Accuracy NPV Radiation Dose mSv Nuclear Medicine vs CTPA PPV 20 Specificity Sensitivity 3.1 1 0% 25% 50% 75% 100% V/Q SPECT/CT V/Q SPECT CTPA V/Q Planar VQ SPECT or Planar VQ SPECT/ CT CTPA Diagnostic ability of V/Q SPECT/CT1, V/Q SPECT1, CTPA1 and V/Q Planar2 to detect PE (adapted from Hess and al,
Slide 46: Technegas vs Xenon-133 vs DTPA Tc99m
Technegas® Easy 3 to 4 breaths 3D images No contraindications Covid-19 Xenon - 133 DTPA Tc99m Wet Aerosol True radioactive No 3D images impacts efficacy, bronchospasm, gas inhaled with limited to planar COVID-19 concerns full face mask imaging resulting in lower sensitivity & specificity Creates hot
Slide 47: USA Commercialisation Pathway
Clinical Regulatory Key Opinion Leaders engaged Australian Site Manufacturing Approved Medical Affairs Director Recruited USFDA Approval Granted Clinical Affairs Director Recruited Majority of State Pharmaceutical Wholesale Recruit Chief Medical Officer 2026. Licenses being Granted R
Slide 48: The importance, urgency and opportunity 'Beyond PE' underway
The importance, urgency and opportunity ‘Beyond PE” underway Lung Disease in 2019 accounted for 6 million deaths 1 worldwide (12% of all deaths) COPD and Lower Respiratory Infections and Lung Cancer 2 will be the 3rd, 4th and 6th largest causes of death by 2030. “Over and underdiagnosis of Lung Dise
Slide 49: Hierarchy of Evidence
Hierarchy of Evidence Technegas has A High Standard of Clinical Evidence to Drive Adoption in Traditional & Beyond PE Applications 49